Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882980 | 0.73 | PIK3CD (0.46) | ALDH1A1TSHRKMT2AMEN1POLB | |
| SCHEMBL23916746 | 0.72 | KCNH2 (0.40) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8892804 | 0.69 | KDM4E (0.55) | ALDH1A1SMN1; SMN2KDM4EGAATSHR | |
| SCHEMBL18859442 | 0.69 | KMT2A (0.41) | SMN1; SMN2TSHRKMT2AMEN1POLB | |
| SCHEMBL26138812 | 0.68 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL26130347 | 0.68 | FPR2 (0.45) | ALDH1A1SMN1; SMN2KDM4EGAATSHR | |
| SCHEMBL14031986 | 0.66 | KMT2A (0.41) | SMN1; SMN2TSHRKMT2AMEN1POLB | |
| SCHEMBL22332263 | 0.65 | ALDH1A1 (0.43) | ALDH1A1TSHRKMT2AMEN1RAB9A | |
| SCHEMBL189570 | 0.65 | FPR2 (0.51) | ALDH1A1SMN1; SMN2KDM4EGAATSHR | |
| SCHEMBL24449428 | 0.64 | RBP4 (0.41) | ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | KRAS, NRAS, G3BP2 | ALDH1A1 1492/4885SMN1; SMN2 1976/4885KDM4E 1473/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | ALDH1A1 1405/4885SMN1; SMN2 1627/4885KDM4E 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.